Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terazosin vs Tamsulosin for Ureteral Stent Related Symptoms
NCT06966804Phase 3Recruiting
- Sponsor
- Hospital Pulau Pinang
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of terazosin and tamsulosin in ureteral stent-related symptoms (USRS) (3 arms), sponsored by Hospital Pulau Pinang. Primary endpoint: Post-stenting urinary symptoms at 14 days. Started Jun 2025; status: recruiting.
02
Drugs
terazosintamsulosin
03
Conditions
ureteral stent-related symptoms (USRS)
Beyond the preview
Go deeper on NCT06966804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966804.